“It’s very important to me that the medical personnel in this state have the right tools and supplies to fight this battle,” said Catherine Ivy, founder and president of the Ben and Catherine Ivy Foundation and co-founder of the Ivy Brain Tumor Center at Barrow Neurological Institute. “While this gift will help, I realize it’s still not enough to fully support those on the frontlines. I want to encourage other foundations and non-profits who can help to please do so. It is my belief that when you have, you share.”
Barrow Neurological Institute neurosurgeon, Dr. Zaman Mirzadeh has received a three-year, $1.8 million grant from the U.S. Department of Defense (DoD) to study the rewiring of the brain to normalize blood sugar levels in diabetes. As a member of the Ivy Center team, Dr. Mirzadeh runs a lab focused on identifying unique metabolic pathways co-opted by glioblastoma to drive tumor growth.
The Ivy Brain Tumor Center at the Barrow Neurological Institute is a nonprofit center conducting early phase clinical trials of new therapeutics for brain tumors. In this interview with Oncology Times, Dr. Nader Sanai explains how the phase 0 trials work and why the center is so excited about them.
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced a partnership with two East Valley hospitals to expand its novel Phase 0 clinical trials program, the first of its kind in neuro-oncology.
Catherine Ivy, who lost her husband a decade ago to a devastating and sudden brain cancer, shares her personal journey of grief and purpose, which led to the founding of the Ivy Brain Tumor Center at the Barrow Neurological Institute.
Brain cancer survivor Lanette Veres sends cards and packages to others with the disease. She believes no one should face cancer alone.
In this edition of The Onco’Zine Brief, Peter Hofland talks with Catherine Ivy about how after losing her husband Ben to glioblastoma she became a tireless advocate for brain cancer patients.
The Ivy Brain Tumor Center at the Barrow Neurological Institute and SonALASense have signed an strategic agreement to jointly test a new and non-invasive drug-device combination, called sonodynamic therapy or SDT, for the treatment of recurrent glioblastoma.
The Ivy Brain Tumor Center at the Barrow Neurological Institute, today announced a strategic collaboration with SonALASense to develop and test a new, non-invasive drug-device combination, sonodynamic therapy (SDT), for recurrent glioblastoma through a Phase 0/2 clinical trial.
Catherine Ivy sat down with Devin Thorpe's Your Mark On The World to discuss her personal fight with glioblastoma and how she hopes to shake up the research process with her investment in the Ivy Center's Phase 0 clinical trials.